News

A review of current literature by Parkinson’s disease researchers worldwide found studies that attempted to classify the disease into a limited number of subtypes fall short in both methods and clinical applications.  New approaches are needed in re-evaluating Parkinson’s disease subtypes, and should include those…

A new model of alpha-synuclein in Parkinson’s development, addressing both where aggregates first appear and their spread through the nervous system, may explain the variety of early symptoms, asymmetry in motor symptoms, and variability of disease progression seen in patients, a study reported. The study,…

Motor deficits, including problems with balance skills and gait or walking speed, are linked with non-motor symptoms of cognition — such as verbal fluency, memory, and attention — in people with Parkinson’s disease, a recent study suggests. Researchers believe these findings may help to identify cognitive deficits and…

Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference. Deep brain stimulation (DBS) can lessen motor function impairments and reduce the need for medication for up to 10 years in…

People with Parkinson’s disease have an altered perception of movement when viewing abstract art as compared with their age- and education-matched healthy peers, a study found. These results suggest that motor responses, aesthetic appreciation, and motion are somehow linked — and that altered neurological function, such as that observed…

Men who experience sleepwalking — alone or in combination with another sleep disorder called rapid eye movement (REM) sleep behavior disorder — are at least four times more likely to develop Parkinson’s disease than those who do not. That finding, which comes from a study of more than 25,000…

Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. People with Parkinson’s disease are using more cannabis-based products, especially those containing cannabidiol (CBD), as a treatment option to ease…

Dose-dependent decreases in targeted fatty acids were seen with YTX-7739, an investigational therapy for Parkinson’s disease, suggesting the medicine engages its therapeutic target, according to the results of a Phase 1a multiple-ascending dose study in healthy volunteers.

The nonprofit Parkinson Canada has teamed up with technology company Catalyst to enhance awareness of available digital health tools that can help people with Parkinson’s disease keep up their medication regimen. People diagnosed with Parkinson’s usually require treatment with multiple medications, often with frequent dosing, to adequately…

Double vision (diplopia) is common in people with Parkinson’s — affecting up to an estimated 30% of patients — and is linked to both motor and non‐motor disease symptoms, a new large-scale, longitudinal study has found. Parkinson’s patients with double vision were more likely to be older, non-white, female,…